Efficacy of the combination of endostar with chemotherapy on stage IVb and recurrent metastatic cervical cancer.

Objectives To observe the efficacy and adverse reactions of the combination of endostar with chemotherapy in the treatment of advanced (IVb) and recurrent metastatic cervical cancer. Methods Forty-four patients with recurrent and metastatic cervical cancer, who were admitted to the Second Xiangya Hospital, Central South University from December 2016 to December 2018 were randomly divided into an experimental group and a control group (22 cases in each group). The control group was given gemcitabine plus cisplatin (GP) or docetaxel plus cisplatin (DP) treatment, the experimental group was treated with endostar on the basis of the control group. Results The objective response rate (ORR) was 42.9% in the experimental group and 22.7% in the control group. There was no significant difference between the 2 groups (P=0.371). The disease control rate (DCR) was 76.2% in the experimental group and 68.2% in the control group. There was no significant difference between the 2 groups (P=0.558). The effect of combined endostar was doubled compared with the effect of non-combination (50.0% vs 27.3% and 36.4% vs 18.2%), but there was no significant difference (P>0.05). Subgroup analysis found no significant difference in DP/GP with or without endostar on DCR (80.0% vs 72.7%, 72.7% vs 63.6%, P>0.05, respectively). The median progression-free survival of the experimental group and the control group were 7.2 months and 5.1 months, respectively, and the difference was statistically significant (P=0.036). The 2 groups mainly showed that the 3-4 adverse reaction was myelosuppression. The incidence of neutropenia of grade III-IV in the experimental group and the control group were 54.5% and 50.0%, respectively, and there was no statistical difference (P>0.05). The incidence of cardiovascular toxicity was higher in the experimental group than that in the control group (13.6% vs 0), but there was no significant difference between the 2 groups (P=0.233). Conclusions Compared with chemotherapy alone, endostar combined with chemotherapy can prolong the median progression-free survival, with higher ORR and similar adverse reactions.